The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study

Deepak L Bhatt, Guillaume Paré, John W Eikelboom, Katy L Simonsen, Eileen S Emison, Keith A A Fox, Ph Gabriel Steg, Gilles Montalescot, Nihar Bhakta, Werner Hacke, Marcus D Flather, Koon-Hou Mak, Patrice Cacoub, Mark A Creager, Peter B Berger, Steven R Steinhubl, Gurunathan Murugesan, Shamir R Mehta, Kandice Kottke-Marchant, A Michael LincoffEric J Topol, CHARISMA Investigators

Research output: Contribution to journalArticlepeer-review

80 Citations (Scopus)

Abstract

Clinical trials have established the value of clopidogrel therapy in a wide spectrum of patients with cardiovascular diseases. Both loss- and gain-of-function single nucleotide variants of CYP2C19 genes have been identified that affect clopidogrel metabolism and anti-platelet response. We sought to determine the impact of CYP2C19 polymorphisms on ischaemic and bleeding events.
Original languageEnglish
Pages (from-to)2143-50
Number of pages8
JournalEuropean Heart Journal
Volume33
Issue number17
DOIs
Publication statusPublished - Sep 2012

Keywords

  • Aryl Hydrocarbon Hydroxylases
  • Atherosclerosis
  • Female
  • Genotype
  • Hemorrhage
  • Heterozygote
  • Humans
  • Ischemia
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Platelet Aggregation Inhibitors
  • Polymorphism, Genetic
  • Stroke
  • Thrombosis
  • Ticlopidine

Cite this